14 - 16 May, 2019 | Hotel Novotel Amsterdam Schiphol Airport, Amsterdam, Netherlands

Media Center

Biosimilars Commercialisation Summit Agenda 2019

The inaugural Biosimilars Commercialisation Summit is the only forum to dive deep into commercial strategy on a global level. Over 3 days of expert case-study presentations and interactive sessions this forum will enable you to tailor your commercial strategy to both established and emergi ...

Speaker Spotlight

Speaker Spotlight- Michael Muenzberg, MD, on the good, the bad and the ugly of the biosimilars market

Pharma IQ caught up with summit chair, Dr Michael Muenzberg, MD, to discuss past successes, current challenges and future opportunities in the biosimilars market. 

Featured Content

Launching Biosimilars in Emerging Markets

In the lead up to the forthcoming “Biosimilars Commercialisation Summit” happening in May 2019, Pharma IQ  had the opportunity to interview industry experts:Jose Carlos Ferreyra, President at Mexican Pharmaceutical Institute Fabiola Santillan, Country Manager at TTY BiopharmPankaj Chaudhari, Manager - Global Regulatory Affairs (Biosimilars) at IQVIAThey shared their thoughts on the...

Biosimilars Investment Trends 2019

We asked commercialisation experts from the biosimilars industry about how they are investing in their development, and market access strategy.Download this piece to learn about:The reasons why companies aren't currently outsourcing The biggest factors in choosing a new solution providerThe biggest challenges in biosimilar commercialisation currently

Switching between Biologics and Biosimilars

Ahead of the Biosimilars Commercialisation Summit Pharma IQ sat down and spoke with Kalveer Flora, Specialist Pharmacist Rheumatology and Biosimilars, London North West Healthcare NHS Trust to talk about the adoption of biosimilars in the market.Download this piece to gain insight into:The importance of offering patients guidance when switching between...

Top 10 Challenges: Producing commercial cell and gene products

The international regenerative medicines market – which includes the likes of cell therapies, gene/gene-modified cell therapy and tissue engineering – is set to climb to around $67 billion by 2020.  Alongside, discovering therapies that will treat cancer and orphan diseases, many in the industry are hungry to land grab market...

Pharmatching Portrays Biosimilars

Due to the complex nature of biosimilars, pharma manufacturers need to rely, partly or to a large extent, on external capacities and expertise. The more classically generic the company’s background, the more this holds true. In this issue of Pharmatching Portrays, we showcase some of the Specialist Providers that have...

5 thoughts for physicians switching patients to biosimilars

In response to the recent bioboom, physicians may consider switching patients to a biosimilar for a more affordable alternative. However, this is a decision that shouldn’t be made in haste and has a few crucial points to be considered.Pharma IQ spoke to The European Trade Association for biopharmaceutical companies (EBE),...

Cell and Gene Theraphy Infographic

Over the last 12 months, the cell and gene therapy manufacturing sphere has matured vastly with more companies advancing to commercial products, especially with allogenic therapies. Now that the theory behind the therapy is catching up with the technology, the two can come together to progress towards producing commercial products.Pharma...

Cell & Gene Manufacturing Process Efficiencies: Best Practice Guide

The level of process efficiency behind today’s cell and gene therapies is said to rest at a low. The manufacturing behind them is mostly manual, due to the treatments mostly being within early development stages. There are, however, some cases where companies utilise partly automated solutions.Pharma IQ spoke with Elena...

Supplying for the Biologics Boom

The rising use of biosimilars  is expected to result in the near doubling of the size of pharma cold chain logistics business over the next three years. Pharma IQ spoke with Javier Gomez-Contreras Supply Chain BGx LATAM of GSK about the prospects for vaccine distribution as the industry serves the...